Covid-19 roundup: BeiGene's re­pur­posed BTK in­hibitor flops in PhII tri­al; Philip­pines sus­pends As­traZeneca's vac­cine af­ter EMA draws link to blood clots

An­oth­er re­pur­posed Covid-19 treat­ment bites the dust.

BeiGene put out word on Thurs­day that Brukin­sa, its man­tle cell lym­phoma drug, flopped in a Phase II tri­al with hos­pi­tal­ized Covid-19 pa­tients who need sup­ple­men­tal oxy­gen.

When com­pared to a place­bo, the small mol­e­cule BTK in­hibitor missed the co-pri­ma­ry end­points of res­pi­ra­to­ry fail­ure-free sur­vival or re­duc­tion in the num­ber of days on oxy­gen, BeiGene said. The tri­al be­gan last May, and en­rolled a to­tal of 67 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER